Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
4.6
$ 17.99
In stock
(316)
Product Description
Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis - JTO Clinical and Research Reports
Critical Review of *EGFR*-Mutated NSCLC What We Do and Do Not Know
Improved survival in patients with unresectable stage III EGFR‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors - Wang - 2022 - Thoracic Cancer - Wiley Online Library
Critical Review of *EGFR*-Mutated NSCLC What We Do and Do Not Know
Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non‐small‐cell lung cancer harboring EGFR mutations: Results from a real‐world study in South Korea - Kim - 2021
Osimertinib shows promise as new standard-of-care treatment for advanced lung cancer
Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study - The Lancet Regional Health – Europe
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study - ScienceDirect
Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non–Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801) - Clinical Lung Cancer
Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer - Jiyun Lee, Zofia Piotrowska, Ross Soo, Byoung Chul Cho, Sun Min Lim, 2022
/cdn.vox-cdn.com/uploads/chorus_asset/file/22481363/1314429956.jpg)
